179 related articles for article (PubMed ID: 16618741)
1. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.
Schmitt E; Maingret L; Puig PE; Rerole AL; Ghiringhelli F; Hammann A; Solary E; Kroemer G; Garrido C
Cancer Res; 2006 Apr; 66(8):4191-7. PubMed ID: 16618741
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant.
Schmitt E; Parcellier A; Gurbuxani S; Cande C; Hammann A; Morales MC; Hunt CR; Dix DJ; Kroemer RT; Giordanetto F; Jäättelä M; Penninger JM; Pance A; Kroemer G; Garrido C
Cancer Res; 2003 Dec; 63(23):8233-40. PubMed ID: 14678980
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
5. Heat-shock protein 70 antagonizes apoptosis-inducing factor.
Ravagnan L; Gurbuxani S; Susin SA; Maisse C; Daugas E; Zamzami N; Mak T; Jäättelä M; Penninger JM; Garrido C; Kroemer G
Nat Cell Biol; 2001 Sep; 3(9):839-43. PubMed ID: 11533664
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor.
Gurbuxani S; Schmitt E; Cande C; Parcellier A; Hammann A; Daugas E; Kouranti I; Spahr C; Pance A; Kroemer G; Garrido C
Oncogene; 2003 Oct; 22(43):6669-78. PubMed ID: 14555980
[TBL] [Abstract][Full Text] [Related]
7. Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells.
Gurbuxani S; Bruey JM; Fromentin A; Larmonier N; Parcellier A; Jäättelä M; Martin F; Solary E; Garrido C
Oncogene; 2001 Nov; 20(51):7478-85. PubMed ID: 11709719
[TBL] [Abstract][Full Text] [Related]
8. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
Dello Russo C; Polak PE; Mercado PR; Spagnolo A; Sharp A; Murphy P; Kamal A; Burrows FJ; Fritz LC; Feinstein DL
J Neurochem; 2006 Dec; 99(5):1351-62. PubMed ID: 17064348
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
11. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
Newcomb EW; Lukyanov Y; Schnee T; Esencay M; Fischer I; Hong D; Shao Y; Zagzag D
Anticancer Drugs; 2007 Sep; 18(8):875-82. PubMed ID: 17667592
[TBL] [Abstract][Full Text] [Related]
12. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Sausville EA
Clin Cancer Res; 2001 Aug; 7(8):2155-8. PubMed ID: 11489788
[No Abstract] [Full Text] [Related]
13. [Inhibitory effect of 4-1BBL combined with Hsp70-tumor antigen peptides on pulmonary metastasis of melanoma in mice].
Qiu H; Zhang GM; Zhang H; Yuan Y; Li D; Feng ZH
Ai Zheng; 2005 Jul; 24(7):781-6. PubMed ID: 16004800
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
15. Protection of zinc against tumor necrosis factor induced lethal inflammation depends on heat shock protein 70 and allows safe antitumor therapy.
Van Molle W; Van Roy M; Van Bogaert T; Dejager L; Van Lint P; Vanlaere I; Sekikawa K; Kollias G; Libert C
Cancer Res; 2007 Aug; 67(15):7301-7. PubMed ID: 17671199
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma.
Aghdassi A; Phillips P; Dudeja V; Dhaulakhandi D; Sharif R; Dawra R; Lerch MM; Saluja A
Cancer Res; 2007 Jan; 67(2):616-25. PubMed ID: 17234771
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
Neckers L
Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
[No Abstract] [Full Text] [Related]
20. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
